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Eur J Vasc Endovasc Surg (2009) 38, 653e655Secure fixation following EVAR with the Powerlink XL System in wide
aortic necks: Results of a prospective, multicenter trial
William D. Jordan Jr, William M. Moore Jr, Jim G. Melton, O. William Brown,
Jeffrey P. Carpenter, for the Endologix Investigators
Purpose: Endovascular stent graft repair of abdominal aortic aneurysms
(AAA) with the Endologix Powerlink System (Endologix, Inc, Irvine, Calif)
has been shown to be a safe and effective alternative to open surgery in
patients having an aortic neck diameter of up to 26 mm. We assessed the
safety and effectiveness of AAA repair in patients with wide aortic necks
(up to 32 mm in diameter) using the Powerlink XL System.
Methods: Between September 2005 and June 2008, a prospective, multi-
center, pivotal US Food and Drug Administration trial of the Powerlink XL
System for endovascular aneurysm repair was conducted at 13 centers. Using
a sizing algorithm based on computed tomography scan (CT)-based measure-
ments, a total of 78 patients (N = 60 [pivotal trial]; N = 18 [continued
access]) presenting with AAA and an infrarenal aortic neck up to 32 mm in
diameter received a bifurcated stent graft via anatomical fixation at the aor-
toiliac bifurcation and proximal sealing with a Powerlink XL infrarenal prox-
imal extension stent graft. Postoperatively, results were assessed with
contrast-enhanced CT scans and abdominal x-rays at one, six, and 12
months, with continued annual follow-up to five years.
Results: Predominantly male (91%), patients presented at a mean age of 73
 8.6 years with mean maximum aortic neck and AAA diameters of 31  1.9
mm (range, 25 to 32 mm) and 5.7  1.0 cm (range, 4.3 to 10 cm), respec-
tively. Challenging infrarenal aortic neck anatomy, defined as the presence
of severe thrombus and/or reverse taper, was present in 85% of patients.
Technical success was achieved in 98.7% of patients, with one patient
requiring femoral-femoral bypass intraoperatively. Aneurysm exclusion was
achieved in 100% of patients over a mean procedure time of 129  66
minutes. Patients were discharged at a mean of 2.2 days postoperatively.
At the one-month CT scan, the independent core lab identified a Type II en-
doleak in 13 patients, distal Type I and Type II endoleak in one patient, and
unknown endoleak in three patients. At 30 days, there were no deaths,
conversions, ruptures, or migrations. Through one year follow-up, Type II en-
doleak predominated (9/10 patients with endoleak), with one proximal Type
I and no Type III, IV, or unknown endoleak; no conversions, ruptures, or
migrations have been observed. The one-year all-cause mortality rate was
6.4%, with 100% freedom from aneurysm-related mortality. Secondary
procedures were performed within one year in five patients (6.4%) for treat-
ment of proximal Type I endoleak (n = 2), proximal Type I/Type II endoleak
(n = 1), and distal Type I endoleak (n = 2). Reduced or stable aneurysm sac
diameter at one year is observed in 96% of patients.
Conclusions: The combination of an anatomically-fixed Powerlink bifur-
cated stent graft and a Powerlink XL infrarenal proximal extension appears
safe and effectively excludes aneurysms in patients with wide aortic necks.
These results suggest that fixation at the aortic bifurcation can provide
secure fixation for patients with large diameter diseased proximal aortic
necks.
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Paul J. Riesenman, James D. Brooks, Mark A. Farber
Background: Thoracic endovascular aortic repair of aortobronchial fistulas
is an emerging treatment modality for this highly lethal condition. The feasi-
bility and long-term durability of this form of intervention are largely
unknown.
Methods: The records of five patients who received endografts to treat aor-
tobronchial fistulas at our institution were reviewed. A literature review was
also conducted using MEDLINE to identify reports detailing outcomes of
patients undergoing thoracic endovascular aortic repair for this condition.
Primary outcome end points included intraoperative mortality, 30-day
mortality, and aortobronchial fistula recurrence.
Results: For the five patients treated at our institution, technical success
was 100%. In follow-up, aortobronchial fistulas recurred in two patients, re-
sulting in one patient death and one endograft explantation. We identified 32
reports that met inclusion for our final review. Inclusive of the five patients
treated at out institution, 67 patients with reported outcomes comprised the
overall analysis. Most patients (55%) had previously undergone thoracic
aortic surgery. Commercially manufactured thoracic endografts were used
in 75% of patients. No intraoperative mortality was reported, and the
30-day mortality was 1.5%. Aortobronchial fistula recurred after endovascu-
lar repair in six patients (9%) through a mean follow-up of 21.5 months. Three
cases of recurrent aortobronchial fistula resulted in patient death.
Conclusions: Thoracic endovascular aortic repair of aortobronchial fistulas
appears to a viable alternative to conventional open repair with excellent
short-term results. Recurrence of the aortobronchial fistula after endovascu-
lar repair is a potential complication necessitating long-term surveillance.
Individual risk assessment is needed to determine if endovascular repair
should be used as bridge therapy or as a definitive repair.
Laparoscopic-assisted treatment of abdominal aortic aneurysm requiring
suprarenal cross-clamping
Mauro Ferrari, Daniele Adami, Raffaella Berchiolli, Andrea Del Corso, Andrea
Pietrabissa
Objective: Hand-assisted laparoscopic surgery (HALS) was previously em-
ployed to treat patients with infrarenal abdominal aortic aneurysm (IAAA).
The use of HALS for juxtarenal abdominal aortic aneurysm (JAAA) has never
been validated. In this study, we report our experience with this technique
to demonstrate its feasibility and prove its safety in dealing with JAAA.
Methods: From October 2000 to October 2008, we have selectively treated
271 patients with abdominal aortic aneurysm with the HALS technique. Of
these, 83 were JAAAs which required a suprarenal aortic clamping (group
A), and 188 were IAAA (group B). General data of the two groups were
analyzed for comparability purposes and operative and postoperative data
were prospectively collected. Additionally, patients in group A were strati-
fied in three classes according to their pre-existing degree of renal function
impairment. Statistical significance was defined at the P < .05 level.
654 AbstractsResults: Mean operative time was 220 minutes  66 in group A and 231
minutes  64 in group B (P > .05). The mean duration of suprarenal clamping
was 28 minutes  6; whereas infrarenal clamping lasted an average of 25
minutes  5 (P > .05). Mean intraoperative blood loss was 1023  584 mL
for group A and 961  633 mL for group B (P > .05). No conversion or 30-
day postoperative mortality was recorded in either group. Sixteen percent
of the patients in group A developed a postoperative complication, vs 11%
in group B (P > .05). Mean postoperative stay for group A and B was 4.2 
1.5 and 4.2  1.9 days, respectively (P > .05). Postoperative kidney function
significantly worsened in 5 patients in group A (6%). A prolonged warm
ischemia time (>40), pre-existing renal dysfunction, and diabetes, corre-
lated to the development of postoperative renal insufficiency. Follow-up
of patients averaged 37.9  20 months. The incidence of incisional hernias
in group A and B was 15.5% vs 11.1%, respectively (P > .05).
Conclusion: The HALS technique proved to be feasible and safe not only for
patients with IAAA, but also for the management of patients with JAAA. No
significant difference could be shown in the comparison between the two
groups, apart from the expected higher rate of postoperative renal dysfunc-
tion after suprarenal clamping. In view of the demonstrated benefit of this
minimally invasive approach, we believe that it should be included among
the alternative options of treatment for these patients.
Duplex ultrasound imaging alone is sufficient for midterm endovascular
aneurysm repair surveillance: A cost analysis study and prospective
comparison with computed tomography scan
Brian R. Beeman, Lynne M. Doctor, Kevin Doerr, Sandy McAfee-Bennett,
Matthew J. Dougherty, Keith D. Calligaro
Objective: Early in our experience with endovascular aortic aneurysm repair
(EVAR) we performed both serial computed tomography scans and duplex
ultrasound (DU) imaging in our post-EVAR surveillance regimen. Later we
conducted a prospective study with DU imaging as the sole surveillance study
and determined cost savings and outcome using this strategy.
Methods: From September 21, 1998, to May 30, 2008, 250 patients under-
went EVAR at our hospital. Before July 1, 2004, EVAR patients underwent
CT and DU imaging performed every 6 months during the first year and then
annually if no problems were identified (group 1). We compared aneurysm
sac size, presence of endoleak, and graft patency between the two scan-
ning modalities. After July 1, 2004, patients underwent surveillance using
DU imaging as the sole surveillance study unless a problem was detected
(group 2). CT and DU imaging charges for each regimen were compared
using our 2008 health system pricing and Medicare reimbursements. All
DU examinations were performed in our accredited noninvasive vascular
laboratory by experienced technologists. Statistical analysis was performed
using Pearson correlation coefficient.
Results: DU and CT scans were equivalent in determining aneurysm sac diam-
eter after EVAR (P< .001). DU and CTwere each as likely to falsely suggest an
endoleak when none existed and were as likely to miss an endoleak. Using DU
imaging alonewould have reduced cost of EVAR surveillance by 29% ($534,356)
in group 1. Cost savings of $1595 per patient per year were realized in group 2
by eliminating CT scan surveillance. None of the group 2 patients sustained an
adverse event such as rupture, graft migration, or limb occlusion as a result of
having DU imaging performed as the sole follow-up modality.
Conclusion: Surveillance of EVAR patients can be performed accurately,
safely, and cost-effectively with DU as the sole imaging study.
Comparative effectiveness of carotid arterial stenting versus
endarterectomy
Peter W. Groeneveld, Lin Yang, Alexis Greenhut, Feifei Yang
Background: Carotid arterial stent (CAS) systems are an alterative to
carotid endarterectomy for the treatment of moderate to severe carotid
stenosis, but the effectiveness of CAS compared to endarterectomy in pre-
venting stroke and death is uncertain. This study’s objective was to compare
the clinical outcomes among Medicare beneficiaries undergoing carotid
revascularization before and after CAS became widely available.
Objectives: Observational, retrospective cohort study of 46,784 patients
undergoing carotid revascularization from August 2005-March 2006 (the
coverage era) compared to propensity-score-matched patients undergoingcarotid revascularization between October 2002-September 2004 (the pre-
coverage era), before widespread Medicare coverage of CAS.
Methods: Mortality was compared at 90 and 270 days after revascularization,
aswere the combined outcomes of periprocedural acutemyocardial infarction
and any stroke or death within 90 and 270 days after revascularization,
between the two eras. Comparisons were also made between localities with
high (23% of carotid procedures being CAS) and lower (9% of carotid procedures
being CAS) adoption rates of carotid stents during the coverage era.
Results: There were no significant differences in 90-day mortality (2.2% vs
2.2%; P = .79), 90-day combined outcomes (4.5% vs 4.3%; P = .13), or 270-
day mortality (4.8% vs 4.6%; P = .17) between the coverage and pre-coverage
eras, but there were more 270-day combined outcomes in the coverage era
(7.7% vs 7.3%; P = .03). In localities with higher adoption of carotid stents,
there was higher 90-day mortality (adjusted odds ratio [OR] 1.15; P = .16),
90-day combined outcomes (OR = 1.17; P = .03), 270-day mortality
(OR = 1.13; P = .07), and 270-day combined outcomes (OR = 1.10; P = .09)
in the coverage era. There were no differences in event rates between eras
in areas with lower carotid stent adoption.
Conclusion: The adoption of carotid stents for treatment of carotid stenosis
was associated with increased rates of adverse clinical outcomes after
carotid revascularization.
Nitinol stenting improves primary patency of the superficial femoral
artery after percutaneous transluminal angioplasty in hemodialysis
patients: A propensity-matched analysis
Yoshihiro Kawamura, Hideki Ishii, Toru Aoyama, Miho Tanaka, Hiroshi
Takahashi, Yoshitaka Kumada, Takanobu Toriyama, Toyoaki Murohara
Background: Although percutaneous transluminal angioplasty (PTA) has
become a common therapeutic standard for peripheral artery disease
(PAD), high restenosis rates in the superficial femoral artery (SFA) remain
a major problem. Nitinol stent implantation is reported to reduce restenosis
in SFA after PTA in the general population; however, little is known about
whether the nitinol stent improves primary patency after PTA in hemodial-
ysis patients who are at higher risk of revascularization failure. The aim of
this study was to clarify the effects of nitinol stent implantation for primary
patency in SFA after PTA in hemodialysis patients with PAD.
Methods: Eighty consecutive hemodialysis patients (167 SFA lesions) who
underwent PTA with nitinol stents from January 2006 to January 2008 were
compared with 64 hemodialysis patients (128 SFA lesions) who received
stainless steel stents in the preceding 2 years. In the follow-up study to 2
years, incidence of restenosis, amputation, and all-cause mortality were
analyzed. End points between the groups were examined with the Kaplan-
Meier and log-rank methods. Prognostic values for end points were calcu-
lated by a Cox univariate analysis and Cox multivariable regression models.
To statistically minimize the differences in each stent group, a propensity-
matched analysis was also performed using the model including male gender,
age, diabetes, hypertension, hyperlipidemia, smoking, incidence of ulcer/
gangrene, and TransAtlantic Inter-Society Consensus (TASC) type C+D.
Results: The 2-year primary patency rate was 58% in the nitinol group vs 42%
in the stainless steel group (hazard ratio [HR], 0.58; 95% confidence interval
[CI], 0.39-0.84; P = .0045), despite a higher prevalence of TASC C+D lesion in
the nitinol group (68% vs 49%, P = .0014). In 108 lesions matched after
propensity score analysis, the primary patency for 2 years was 64% in the
nitinol group vs 42% in the stainless steel group (HR, 0.39; 95% CI, 0.24-
0.65; P = .0003). Cox multivariate models showed nitinol stent (HR, 0.42;
95% CI, 0.25-0.73; P = .002), age (HR, 1.04; 95% CI, 1.01-1.08; P = .031),
and incidence of ulcer/gangrene (HR, 2.35; 95% CI, 1.17-4.75; P = .017) were
independent predictors of restenosis.
Conclusion: These data suggest that nitinol stent implantation improves
primary patency in SFA after PTA compared with the stainless steel stent,
even in hemodialysis patients with PAD.
Peripheral arterial interventions: Trends in market share and outcomes
by specialty, 1998-2005
Mohammad H. Eslami, Nicholas Csikesz, Andres Schanzer, Louis M. Messina
Objective: Vascular surgeons (VS), interventional cardiologists (IC), and in-
terventional radiologists (IR) perform peripheral arterial interventions (PAI).
Abstracts 655In this study, we reviewed market share trends and compared outcomes for
each specialty using the National Inpatient Sample (NIS).
Methods: Patient discharges for PAI (1998-2005) were identified based on
ICD9-CM procedure codes. The provider’s specialty was identified by
a specialty-specific algorithm and analyzed using SAS 9.1 (SAS Institute,
Cary, NC). Market share trends and distribution of cases at teaching versus
non-teaching hospitals were evaluated. Primary outcome measures were
in-hospital mortality and iatrogenic arterial injuries (IAI). Multivariate
logistic regression was performed to identify independent predictors of
post-procedure morbidity and mortality.
Results: The number of cases identified was 23,825. From 1998 to 2005, IR’s
market share decreased six-fold (1998: 33% to 2005: 5.6%) whereas VS market
share increased from 27% to 43% and IC from 10% to 29% (P < .05). A similar
but more pronounced trend was observed at teaching hospitals. In-hospital
mortality rate was highest for IR (2.1 IR% vs 1.2% VS and 0.6% IC; P < .001).
Post-procedure IAI was highest in the IC group (1.3% vs IR 0.9% and 0.5% VS;
P < .05). Compared with VS, the mortality rate was 1.62 times higher for IR
patients (odds ratio [OR]: 1.62, 95% confidence interval [CI]: 1.16-2.24) and
IAI was 2.44 times higher for IC (OR: 2.44, 95% CI: 1.63-3.66) and 1.75 times
higher for IR (OR: 1.75, 95% CI: 1.08-2.81) patients.
Conclusions: IR market share of PAI has precipitously declined while those
of VS and IC have increased significantly. Vascular surgeons had the lowest
overall morbidity and mortality of all groups. Increase in the number of en-
dovascularly-trained VS with better access to fluoroscopy units may further
increase VS’s market share.The Society for Vascular Surgery Practice Guidelines: Management of the
left subclavian artery with thoracic endovascular aortic repair
Jon S. Matsumura, W. Anthony Lee, R. Scott Mitchell, Mark A. Farber,
Mohammad Hassan Murad, Alan B. Lumsden, Roy K. Greenberg, Hazim J.
Safi, Ronald M. Fairman, for the Society for Vascular Surgery
The Society for Vascular Surgery pursued development of clinical practice
guidelines for the management of the left subclavian artery with thoracic en-
dovascular aortic repair (TEVAR). In formulating clinical practice guidelines,
the society selected a panel of experts and conducted a systematic review
and meta-analysis of the literature. They used the grading of recommenda-
tions assessment, development, and evaluation (GRADE) method to develop
and present their recommendations. The overall quality of evidence was very
low. The committee issued three recommendations. Recommendation 1: In
patients who need elective TEVAR where achievement of a proximal seal
necessitates coverage of the left subclavian artery, we suggest routine preop-
erative revascularization, despite the very low-quality evidence (GRADE 2,
level C). Recommendation 2: In selected patients who have an anatomy that
compromises perfusion to critical organs, routine preoperative LSA revascu-
larization is strongly recommended, despite the very low-quality evidence
(GRADE 1, level C). Recommendation 3: In patients who need urgent TEVAR
for life-threatening acute aortic syndromes where achievement of a proximal
seal necessitates coverage of the left subclavian artery,we suggest that revas-
cularization should be individualized and addressed expectantly on the basis
of anatomy, urgency, and availability of surgical expertise (GRADE 2, level C).
